Description
Heptanoyl-coenzyme A (heptanoyl-CoA) is a derivative of CoA (Item Nos. 16147 | 21499 | 21722) that contains the medium-chain fatty acid heptanoic acid (Item No. 33672).1 It inhibits butyryl-CoA:acetate-CoA transferase isolated from the gut bacteria P. elsdenii when used at a concentration of 200 µM. Heptanoyl-CoA levels are increased in primary fibroblasts derived from patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in the presence of heptanoic acid, indicating heptanoyl-CoA formation by short-chain acyl-transferases.2 It blocks decreases in infarct volume and improvements in motor function induced by the isoquinoline alkaloid berberine (Item No. 10006427) in a mouse model of ischemic stroke induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 0.4 mg/kg per day.3WARNING This product is not for human or veterinary use.
References
[1] M SCHULMAN D V. Kinetics and catalytic properties of coenzyme A transferase from Peptostreptococcus elsdenii.[J]. Journal of Bacteriology, 1976, 128 1: 372-381. DOI:
10.1128/jb.128.1.372-381.1976[2] ANURADHA KARUNANIDHI . Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency[J]. Molecular genetics and metabolism, 2023, 140 3: Article 107689. DOI:
10.1016/j.ymgme.2023.107689[3] DUAN H, HU J, DENG Y, et al. Berberine Mediates the Production of Butyrate to Ameliorate Cerebral Ischemia via Gut Microbiota in Mice[C]//17 1. 2023: 0. DOI:
10.20944/preprints202310.1351.v1
